Description
mRNA-4359 is an experimental medicine being developed by ModernaTX, Inc. It is currently being studied in clinical trials for people with advanced solid tumors, including colorectal cancer. The trials are in Phase 1, which means they are primarily focused on determining the safety and best way to give the drug. These trials are looking at mRNA-4359 both by itself and in combination with other immunotherapy drugs (like pembrolizumab, ipilimumab, and nivolumab) that help the immune system fight cancer. The trials are actively recruiting participants. The specific goal is to see how safe mRNA-4359 is and what the best dose might be when used alone or with other treatments. The trials are also looking at people with specific genetic changes (mutations) in their tumors, such as ALK, EGFR, or ROS1 mutations, and also considering PD-L1 expression and MSI status.
Mechanism of Action
mRNA-4359 is a novel type of medicine. The specific way it works (its mechanism of action) is still being investigated in clinical trials. It is designed to interact with the body's cells, potentially influencing how they respond to cancer or other treatments. The trials are evaluating its effects when used alone and in combination with immune checkpoint inhibitors.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.